Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1715-1719

  Nitta, Hidetoshi ^a   Murakami, Yoji ^a   Wada, Yoshihiro ^a   Eto, Masatoshi ^a   Baba, Hideo ^a   Imamura, Takahisa ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

C5a; Cancer; CD88; Invasion; Protease; Receptor

Indexed keywords

ANAPHYLATOXIN; APROTININ; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; SERINE PROTEINASE; C5AR1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SUPERNATANT; TOXIN SYNTHESIS; TUMOR INVASION; TUMOR MICROENVIRONMENT; HCT116 CELL LINE; IMMUNOLOGY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE; TUMOR ESCAPE;

CELL LINE, TUMOR; COMPLEMENT C5; COMPLEMENT C5A; HCT116 CELLS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ANAPHYLATOXIN C5A; SERINE PROTEASES; TUMOR ESCAPE;

EID: 84923068361     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3341     Document Type: Article

References (36)

1. Ricklin D, Hajishengallis G, Yang K and Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797, 2010.
2. Niculescu F, Rus HG, Retegan M and Vlaicu R: Persistent complement activation on tumor cells in breast cancer. Am J Pathol 140: 1039-1043, 1992.
3. Bjørge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE and Meri S: Ascitic complement system in ovarian cancer. Br J Cancer 92: 895-905, 2005. (Pubitemid 40462637)
4. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G and Lambris JD: Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225-1235, 2008.
5. Corrales L, Ajona D, Rafail S, et al: Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 189: 4674-4683, 2012.
6. Müller-Eberhard HJ: Molecular organization and function of the complement system. Annu Rev Biochem 57: 321-347, 1988.
7. Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M and Imai Y: Protection of thyroid cancer cells by complementregulatory factors. Cancer 73: 2808-2817, 1994. (Pubitemid 24166270)
8. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ and Dalmasso AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149: 129-142, 1996. (Pubitemid 26230985)
9. Jurians K, Ziegler S, Garcia-Schüller H, Kraus S, Bohana- Kashtan O, Fishelson Z and Kirschfink M: Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36: 929-939, 1999. (Pubitemid 30100845)
10. Morgan J, Spendlove I and Durrant L: The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens 60: 213-223, 2002. (Pubitemid 35398824)
11. Gancz D and Fishelson Z: Cancer resistance to complementdependent cytotoxicity (CDC): problem-oriented research and development. Mol Immunol 46: 2794-2800, 2009.
12. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD and Song WC: The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201: 567-577, 2005. (Pubitemid 40289547)
13. Mikesch JH, Buerger H, Simon R and Brandt B: Decayaccelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta 1766: 42-52, 2006. (Pubitemid 44175633)
14. Guo RF and Ward PA: Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821-852, 2005.
15. Markiewski MM and Lambris JD: The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171: 715-727, 2007. (Pubitemid 47440971)
16. Nozaki M, Raisler BJ, Sakurai E, et al: Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 103: 2328-2333, 2006. (Pubitemid 43271669)
17. Gerard NP and Gerard C: The chemotactic receptor for human C5a anaphylatoxin. Nature 349: 614-617, 1991. (Pubitemid 21912116)
18. Nitta H, Wada Y, Kawano Y, et al: Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res 19: 2004-2013, 2013.
19. Huber-Lang M, Sarma JV, Zetoune FS, et al: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12: 682-687, 2006. (Pubitemid 43865238)
20. Nitta H, Imamura T, Wada Y, Irie A, Kobayashi H, Okamoto K and Baba H: Production of C5a by ASP, a serine protease released from Aeromonas sobria. J Immunol 181: 3602-3608, 2008.
21. Huber-Lang M, Younkin EM, Sarma JV, et al: Generation of C5a by phagocytic cells. Am J Pathol 161: 1849-1859, 2002. (Pubitemid 35265542)
22. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245, 1987. (Pubitemid 17082655)
23. Kobayashi H, Utsunomiya H, Yamanaka H, Sei Y, Katunuma N, Okamoto K and Tsuge H: Structural basis for the kexin-like serine protease from Aeromonas sobria as sepsis-causing factor. J Biol Chem 284: 27655-27663, 2009.
24. Nitta H, Kobayashi H, Irie A, Baba H, Okamoto K and Imamura T: Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria. FEBS Lett 581: 5935-5939, 2007. (Pubitemid 50012822)
25. Tian S and Jianhua W: Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors. Int J Biol Sci 6: 89-95, 2010.
26. Pintigny D and Dachary-Prigent J: Aprotinin can inhibit the proteolytic activity of thrombin. A fluorescence and enzymatic study. Eur J Biochem 207: 89-95, 1992.
27. Maeda H, Fang J, Inutsuka T and Kitamoto Y: Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 3: 319-328, 2003. (Pubitemid 36293960)
28. Angliker H, Wilkstrom P, Shaw E, Brenner C and Fuller RS: The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J 293: 75-81, 1993. (Pubitemid 23223148)
29. DiScipio RG, Smith CA, Müller-Eberhard HJ and Hugli TE: The activation of human complement C5 by a fluid phase C5 convertase. J Biol Chem 258: 10629-10636, 1983. (Pubitemid 14244323)
30. Antonini E, Ascenzi P, Bolognesi M, Gatti G, Guameri M and Menegatti E: Interaction between serine (pro)enzymes, and Kazal and Kunitz inhibitors. J Mol Biol 165: 543-558, 1983.
31. Angliker H: Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J Med Chem 38: 4014-4018, 1995.
32. Szabo R and Bugge TH: Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol 27: 213-235, 2011.
33. Condeelis J and Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006. (Pubitemid 43121975)
34. van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH and van Egmond M: The role of macrophages in tumor development. Cell Oncol 27: 203-213, 2005. (Pubitemid 43086474)
35. Crowther M, Brown NJ, Bishop ET and Lewis CE: Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol 70: 478-490, 2001. (Pubitemid 32954759)
36. Nozawa H, Chiu C and Hanahan D: Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103: 12493-12498, 2006. (Pubitemid 44267286)